Further related to NSCLC standard of care therapy, A549.R2 cells acquired several characteristics that can modulate the tumour microenvironment, which could impact the response to standard of care immunotherapies like anti-PD-1/PD-L1 blockers. Here, CD274 is linked to neoplasm.